Sales Support:
sales@worldwidemarketreports.com
U.S. :+1 415 871 0703
U.K. :+44-203-289-4040
AUS. : +61-2-4786-0457
INDIA :+91-848-285-0837
Menu Icon Close Icon

Global Glucagon-Like Peptide 1 (GLP-1) Agonist market (2024 Edition): Analysis by Type (Tirzepatide, Semaglutide, Dulaglutide, Others), End-Use (Type 2 Diabetes, NASH, Obesity), By Distribution Channel, By Route of Administration, By Region, By Country: Market Insights and Forecast (2020-2030)

Executive Summary

Azoth Analytics has released a research report titled "Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market (2024 Edition)" which provides a complete analysis of the Global Glucagon-Like Peptide 1 (GLP-1) Agonist industry in terms of market segmentation By Type (Tirzepatide, Semaglutide, Dulaglutide, and Other Types), By Distribution Channel (Clinics, Ambulatory Surgical Centers, and Hospitals), By Route of Administration (Oral, and Parenteral) By End-Use (Type 2 Diabetes, NASH, and Obesity), for the historical period of 2020-2023, the estimates of 2023 and the forecast period of 2024-2030.

The research report covers a detailed analysis of the Region (Americas, Europe, Asia Pacific, and Middle East and Africa) and Countries (United States, Canada, UK, Germany, France, Italy, India, China, Japan, South Korea). Additionally, the research report presents data including market size, yearly growth & potential analysis, the competitive study of market players, investment opportunities, and demand forecast. The research report also assesses growth indicators, restraints, supply and demand risk, and other important statistics, as well as a full assessment of current and future market trends that are relevant to the market evolution.

The Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market showcased growth at a CAGR of 20.6% during 2020-2023. The market was valued at USD 18.75 Billion in 2022 which is expected to reach USD 133.5 Billion in 2030. The demand for GLP-1 agonists extends globally, with both developed and developing regions contributing to market growth. Emerging economies are witnessing a rising prevalence of T2DM, driving the need for effective diabetes management strategies, including GLP-1 agonist therapies. The market includes a variety of GLP-1 agonist drugs, both short-acting and long-acting formulations, offering different options for healthcare providers and patients. These drugs are administered via subcutaneous injection or, in some cases, orally.

GLP-1 agonists are known for their efficacy in improving glycemic control in patients with T2DM, often leading to reductions in HbA1c levels and fasting plasma glucose levels. Additionally, these drugs are associated with weight loss, making them particularly beneficial for obese individuals with diabetes.

Several GLP-1 agonists have demonstrated cardiovascular benefits in clinical trials, including reductions in major adverse cardiovascular events (MACE) such as heart attack, stroke, and cardiovascular death. These findings have contributed to the growing adoption of GLP-1 agonists in patients with T2DM and established cardiovascular disease (CVD) or high cardiovascular risk.

While GLP-1 agonists are primarily administered via subcutaneous injections, efforts are underway to develop alternative delivery methods, such as oral formulations and once-weekly injections, to improve patient adherence and convenience. These innovations aim to address potential barriers to treatment adherence and enhance patient satisfaction.



Scope of the Report

• The report analyses the Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market by Value (USD Million).

• The report presents the analysis of the Global Glucagon-Like Peptide 1 (GLP-1) Agonist market for the historical period of 2020-2023, the estimated year 2023, and the forecast period of 2024-2030.

• The report analyses the Global Glucagon-Like Peptide 1 (GLP-1) Agonist market by Type (Tirzepatide, Semaglutide, Dulaglutide, and Other Types).

• The report analyses the Global Glucagon-Like Peptide 1 (GLP-1) Agonist market by Distribution Channel (Clinics, Ambulatory Surgical Centers, and Hospitals).

• The report analyses the Global Glucagon-Like Peptide 1 (GLP-1) Agonist market by Route of Administration (Oral, and Parenteral).

• The report analyses the Global Glucagon-Like Peptide 1 (GLP-1) Agonist market by End-Use (Type 2 Diabetes, NASH, and Obesity).

• The key insights of the report have been presented through the frameworks of SWOT and Porter's Five Forces Analysis. Also, the attractiveness of the market has been presented by region, By Type, By Distribution Channel, By Route of Administration & By End-Use.

• Also, the major opportunities, trends, drivers, and challenges of the industry have been analyzed in the report.

• The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analyzed in the report include Eli Lilly and Company, Pfizer, Sanofi, AstraZeneca PLC, Boehringer Ingelheim, and Novo Nordisk.

1. Market Background

1.1 Scope and Product Outlook

1.2 Executive Summary

1.3 Research Methodology

2. Strategic Recommendations

3. Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Historic and Forecast (2020-2030)

3.1 Impact Analysis of Macro Economic Factors on Glucagon-Like Peptide 1 (GLP-1) Agonist Market

3.2 Pipeline Analysis of GLP-1 Agonist Market

3.3 Global Obesity Statistics 2022, in Millions

3.4 Diabetes Statistics

3.5 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Dashboard

3.6 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Value Assessment, 2020-2030 (USD Million)

3.7 Impact of COVID-19 on Glucagon-Like Peptide 1 (GLP-1) Agonist Market

3.8 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By Type

3.8.1 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Type Overview

3.8.2 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Tirzepatide, By Value, 2020H-2030F (USD Million & CAGR)

3.8.3 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Semaglutide, By Value, 2020H-2030F (USD Million & CAGR)

3.8.4 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Dulaglutide, By Value, 2020H-2030F (USD Million & CAGR)

3.8.5 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Other Types, By Value, 2020H-2030F (USD Million & CAGR)

3.9 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By Distribution Channel

3.9.1 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel Overview

3.9.2 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Clinics, By Value, 2020H-2030F (USD Million & CAGR)

3.9.3 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Ambulatory Surgical Centers, By Value, 2020H-2030F (USD Million & CAGR)

3.9.4 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)

3.10 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By Route of Administration

3.10.1 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration Overview

3.10.2 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Oral, By Value, 2020H-2030F (USD Million & CAGR)

3.10.3 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)

3.11 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By End-Use

3.11.1 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use Overview

3.11.2 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Type 2 Diabetes, By Value, 2020H-2030F (USD Million & CAGR)

3.11.3 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By NASH, By Value, 2020H-2030F (USD Million & CAGR)

3.11.4 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Obesity, By Value, 2020H-2030F (USD Million & CAGR)

4. Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Regional Analysis

4.1 Regional Coverage of the Study

4.2 Regional Snapshot

5. Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Historic and Forecast (2020-2030)

5.1 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Snapshot

5.2 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Value Assessment, 2020-2030 (USD Million & CAGR)

5.3 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Key Factors

5.4 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Value Assessment

5.5 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Dynamics

5.6 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By Distribution Channel

5.6.1 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel Overview

5.6.2 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Clinics, By Value, 2020H-2030F (USD Million & CAGR)

5.6.3 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Ambulatory Surgical Centers, By Value, 2020H-2030F (USD Million & CAGR)

5.6.4 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)

5.7 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By Route of Administration

5.7.1 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration Overview

5.7.2 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Oral, By Value, 2020H-2030F (USD Million & CAGR)

5.7.3 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)

5.8 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By End-Use

5.8.1 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use Overview

5.8.2 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Type 2 Diabetes, By Value, 2020H-2030F (USD Million & CAGR)

5.8.3 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By NASH, By Value, 2020H-2030F (USD Million & CAGR)

5.8.4 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Obesity, By Value, 2020H-2030F (USD Million & CAGR)

5.9 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By Country

5.9.1 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Country Overview

5.9.2 United States Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)

5.9.2.1 United States Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel

5.9.2.2 United States Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration

5.9.2.3 United States Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use

5.9.3 Canada Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)

5.9.3.1 Canada Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use

5.9.3.2 Canada Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration

5.9.3.3 Canada Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel

5.9.4 Rest of Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)

5.9.4.1 Rest of Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use

5.9.4.2 Rest of Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration

5.9.4.3 Rest of Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel

6. Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Historic and Forecast (2020-2030)

6.1 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Snapshot

6.2 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Value Assessment, 2020-2030 (USD Million & CAGR)

6.3 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Key Factors

6.4 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Value Assessment

6.5 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Dynamics

6.6 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By Distribution Channel

6.6.1 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel Overview

6.6.2 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Clinics, By Value, 2020H-2030F (USD Million & CAGR)

6.6.3 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Ambulatory Surgical Centers, By Value, 2020H-2030F (USD Million & CAGR)

6.6.4 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)

6.7 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By Route of Administration

6.7.1 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration Overview

6.7.2 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Oral, By Value, 2020H-2030F (USD Million & CAGR)

6.7.3 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)

6.8 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By End-Use

6.8.1 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use Overview

6.8.3 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Type 2 Diabetes, By Value, 2020H-2030F (USD Million & CAGR)

6.8.4 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By NASH, By Value, 2020H-2030F (USD Million & CAGR)

6.8.5 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Obesity, By Value, 2020H-2030F (USD Million & CAGR)

6.9 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By Country

6.9.1 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Country Overview

6.9.2 United Kingdom Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)

6.9.2.1 United Kingdom Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel

6.9.2.2 United Kingdom Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration

6.9.2.3 United Kingdom Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use

6.9.3 Germany Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)

6.9.3.1 Germany Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel

6.9.3.2 Germany Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration

6.9.3.3 Germany Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use

6.9.4 France Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)

6.9.4.1 France Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel

6.9.4.2 France Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration

6.9.4.3 France Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use

6.9.5 Italy Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)

6.9.5.1 Italy Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel

6.9.5.2 Italy Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration

6.9.5.3 Italy Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use

6.9.6 Rest of Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)

6.9.6.1 Rest of Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel

6.9.6.2 Rest of Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration

6.9.6.3 Rest of Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use

7. Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Historic and Forecast (2020-2030)

7.1 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Snapshot

7.2 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Value Assessment, 2020-2030 (USD Million & CAGR)

7.3 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Key Factors

7.4 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Value Assessment

7.5 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Dynamics

7.6 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By Distribution Channel

7.6.1 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel Overview

7.6.2 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Clinics, By Value, 2020H-2030F (USD Million & CAGR)

7.6.3 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Ambulatory Surgical Centers, By Value, 2020H-2030F (USD Million & CAGR)

7.6.4 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)

7.7 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By Route of Administration

7.7.1 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration Overview

7.7.2 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Oral, By Value, 2020H-2030F (USD Million & CAGR)

7.7.3 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)

7.8 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By End-Use

7.8.1 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use Overview

7.8.2 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Type 2 Diabetes, By Value, 2020H-2030F (USD Million & CAGR)

7.8.3 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By NASH, By Value, 2020H-2030F (USD Million & CAGR)

7.8.4 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Obesity, By Value, 2020H-2030F (USD Million & CAGR)

7.9 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By Country

7.9.1 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Country Overview

7.9.2 China Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)

7.9.2.1 China Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel

7.9.2.2 China Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration

7.9.2.3 China Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use

7.9.3 Japan Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)

7.9.3.1 Japan Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel

7.9.3.2 Japan Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration

7.9.3.3 Japan Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use

7.9.4 South Korea Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)

7.9.4.1 South Korea Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel

7.9.4.2 South Korea Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration

7.9.4.3 South Korea Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use

7.9.5 India Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)

7.9.5.1 India Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel

7.9.5.2 India Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration

7.9.5.3 India Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use

7.9.6 Rest of Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)

7.9.6.1 Rest of Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel

7.9.6.2 Rest of Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration

7.9.6.3 Rest of Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use

8. Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Historic and Forecast (2020-2030)

8.1 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Snapshot

8.2 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Value Assessment, 2020-2030 (USD Million & CAGR)

8.3 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Key Factors

8.4 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Value Assessment

8.5 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Dynamics

8.6 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By Distribution Channel

8.6.1 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel Overview

8.6.2 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Clinics, By Value, 2020H-2030F (USD Million & CAGR)

8.6.3 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Ambulatory Surgical Centers, By Value, 2020H-2030F (USD Million & CAGR)

8.6.4 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)

8.7 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By Route of Administration

8.7.1 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration Overview

8.7.2 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Oral, By Value, 2020H-2030F (USD Million & CAGR)

8.7.3 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)

8.8 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By End-Use

8.8.1 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use Overview

8.8.2 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Type 2 Diabetes, By Value, 2020H-2030F (USD Million & CAGR)

8.8.3 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By NASH, By Value, 2020H-2030F (USD Million & CAGR)

8.8.4 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Obesity, By Value, 2020H-2030F (USD Million & CAGR)

9. Market Dynamics

9.1 Impact Assessment of Market Dynamics on Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market

9.2 Drivers

9.3 Restraints

9.4 Trends

10. Industry Ecosystem Analysis

10.1 Porter's Five Forces Model

11. Competitive Positioning

11.1 Companies' Product Positioning

11.2 Market Share Analysis of Glucagon-Like Peptide 1 (GLP-1) Agonist Market

11.3 Company Profiles

11.3.1 Eli Lilly and Company

11.3.2 Pfizer

11.3.3 Sanofi

11.3.4 AstraZeneca PLC

11.3.5 Boehringer Ingelheim

11.3.6 Novo Nordisk

Choose License Type

Happy To Assist You

Contact Images

We will be happy to help you find what you need. Please call us or write to us:

Frequently Asked Questions

This report incorporates the analysis of factors that augments the market growth. Report presents competitive landscape of the global market. This also provides the scope of different segments and applications that can potentially influence the market in the future. The analysis is based on current market trends and historic growth data. It includes detailed market segmentation, regional analysis, and competitive landscape of the industry.
The report efficiently evaluates the current market size and provides industry forecast. The market was valued at xxx Million US$ in 2019, and is expected to grow at a CAGR of xx% during the period 2020-2027.
The report efficiently evaluates the current market size and provides forecast for the industry in terms of Value (US$ Mn) and Volume (Thousands Units).
Market is segmented by:
  • Product Types
  • Drug Class
  • Indication
  • Applications
  • Services Types
  • End-users
  • Distribution channel
  • Regions
The report share key insights on the following:
  • Current market size
  • Market forecast
  • Market opportunities
  • Key drivers
  • Restraints
  • Pipeline Analysis
  • Incidence Rate
  • Epidemiology Analysis
  • Prevalence rate
  • Regulatory scenario
  • Industry trend
  • Pestle Analysis
  • Porter’s Analysis
  • New product approvals/launch
  • Promotion and marketing initiatives
  • Pricing analysis
  • Export-import analysis
  • Trade analysis
  • Competitive landscape
It helps the businesses in making investments decisions.
Customization helps the organization to gain insight on specific segments and regions of interest. Thus, WMR offers tailored report information based on business requirement in order to take strategic calls.

Related Reports

PPMO (Peptide-PMO Conjugates) Therapy Market Size And Share Analysis - Growth Trends And Foreca...
View More
Peptide Modification Service Market Size And Share Analysis - Growth Trends And Forecasts (2024...
View More
Peptide Synthesis CDMO Services Market Size And Share Analysis - Growth Trends And Forecasts (2...
View More
GLP-1 Peptide Drugs Market Size And Share Analysis - Growth Trends And Forecasts (2024-2031)
View More
Custom Peptide Pool Service Market Size And Share Analysis - Growth Trends And Forecasts (2024-...
View More

Trusted Clients
A-T- Kearney.png
AbbVie.png
Agrinos.png
AIF-Metrics.png
Akzo-Nobel.jpg
Alfi-GMBH.png
Allergan.png
Almasra-Scientific-Bureau.jpg
ALPMA.jpg
Americana-Foods.png
ANP.png
Aptar-Group-Germany.jpg
asahi-kasei.png
ATC.png
atlas-servair.jpg
ATOS.png
Avalon.png
biofishency.png
biomx.png
borealisgroup.png
Cape-Peninsula.png
CBRE.png
Cennerv-Pharma.jpg
Clearponds.png
Compass-Group.png
Cortag-Industria.png
Covis-Pharma.jpg
DAIMLER-AG.jpg
Edipresse-Media.jpg
Epson.png
Evonik-Industries-AG.png
ExcelSource.png
Fingo.png
Firstkind.png
FLM-Foodingredients.png
Freudenberg.png
Fueltrax.jpg
Fugro-International.png
Fuji-Films.png
Funky-Sound-Studio.png
GALTWAY.png
Gartner.png
GBSC.png
Global-Information.jpg
Hanwha-Total-Petrochemical.png
Hebrew.png
Horiba-Mira.png
Hunter-and-Co-Investments.png
Hyosung.png
Hyssopus-Organics.jpg
IBSA.png
Ideagen.png
IMS.png
InSinkErator.png
Intas-Pharma.png
IntelMed-Sarl.png
Interdiligence-Consulting.png
Israel-Shopyards.png
Johnsons-Controls.png
kakaxi.jpg
KORDSA.png
kotra.png
KPMG.png
lantmannen.png
LEK.png
LG.jpg
Makuri-Technology.jpg
Mallinckrodt.png
Mappo.png
Maprimed.jpg
mcns.jpg
MED-EL.png
Mehr-Azin-Pouya-Sahand.png
Molkerei-Ammerland-eG.png
Monty-Holding.jpg
mpmaterials.png
Mundipharma.png
Nasco.png
Nitto.png
Nouryon.png
NOXTAK.png
Oskars.png
Paidotribo.png
Parnell-Pharmaceuticals.png
Podravka.png
ppg.png
Privi.png
Publicis Groupe.png
Qvetech.jpg
R3P.jpg
Samsung.png
Sapient.png
SEW-EURODRIVE.png
Shivananda.jpg
Silver-Clouds.png
SMIT.jpg
SOLVIAS.png
Spectrum.png
SR-Instruments-Oy.png
Star-Seed.png
Stryker -ENT.png
Synjenta.png
Terumo-Corp.png
TherOzone.png
Toshiba.png
TT-Electronics.png
umbc.edu.png
Vard.jpg
Vital-Xense.png
Walraven.png
Wlgore.png
Woodmac.png
WWF-UK.png
ZENOAQ.png
Zuellig-Pharma.png
Contact us

sales@worldwidemarketreports.com

mapicon
Sales Office (U.S.):
Worldwide Market Reports, 533 Airport Boulevard, Suite 400, Burlingame, CA 94010, United States

mapicon+1-415-871-0703

mapicon
Asia Pacific Intelligence Center (India):
Worldwide Market Reports, 403, 4th Floor, Bremen Business Center, Aundh, Pune, Maharashtra 411007, India.

phoneiconU.S. : +1 415 871 0703

phoneiconU.K. : +44-203-289-4040

phoneiconAUS. :+61-2-4786-0457

phoneiconIndia :+91-848-285-0837

Menu
Quick Links
Newsletter

Want us to send you latest updates of the current trends, insights, and more, signup to our newsletter (for alerts, special offers, and discounts).


Secure Payment By:
paymenticon

This website is secured Origin CA certificate on the server, Comodo, Firewall and Verified Sitelock Malware Protection

secureimg

© 2024 Worldwide Market Reports. All Rights Reserved